



**ASX & MEDIA RELEASE
4 APRIL, 2012**

**MARSHALL EDWARDS ANNOUNCES DATA FROM CLINICAL TRIAL OF ME-143
SELECTED FOR PRESENTATION AT ASCO ANNUAL MEETING**

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement:

San Diego – 3 April, 2012 – Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that data from a Phase I clinical trial of the Company's lead drug candidate ME-143 has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held 1-5 June, 2012, in Chicago. An abstract of the presentation, entitled "ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study," will be available online at www.asco.org approximately two weeks before the Annual Meeting.

"This represents an exciting opportunity to present the data from our trial of ME-143 to oncology thought leaders from around the world," said Robert Mass MD, Chief Medical Officer of Marshall Edwards. "These data will be instrumental as we prepare for the first of our randomised Phase II clinical trials later this year. We are grateful for the ongoing commitment of the clinical investigators, trial coordinators and especially the patients who participated in this study."

Marshall Edwards recently completed enrolment of the fourth cohort in the Phase I clinical trial of ME-143. The dose-escalation trial is evaluating the safety and tolerability of ME-143 in patients with refractory solid tumours. In addition, the trial is designed to characterise the pharmacokinetic profile of intravenous ME-143 and describe any preliminary clinical anti-tumour activity observed. The multi-centre trial is being conducted in collaboration with the Sarah Cannon Research Institute.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company's lead drug candidates, ME-143 and ME-344, have been shown to interact with specific enzyme targets resulting in inhibition of tumour cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September, 2011 and plans to present safety and pharmacokinetic data from the trial at the American Society of Clinical Oncology Annual Meeting in June 2012. The company submitted an Investigational New Drug application for ME-344 in March, 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumours immediately following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	:	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922